Rappaport B Z, Fausti S A, Schechter M A, Frey R H
Scand Audiol. 1986;15(2):67-71. doi: 10.3109/01050398609045956.
Orally administered, neomycin is reported to cause ototoxicity rarely. Most reports on hearing loss due to oral neomycin have been case studies. One prospective study of a pediatric sample demonstrated a significant loss of hearing in the frequency range of 2 to 8 kHz in 9 of 17 children. To our knowledge there are no published prospective studies on this type with adult samples and therefore little is known of the true incidence or nature of ototoxicity from oral neomycin. This prospective study presents the results of long-term use of oral neomycin in 30 adult subjects. Hearing sensitivity was serially monitored in the frequency range 250-20,000 Hz. Two of the 30 subjects subsequently revealed ototoxicity. Thus the results of this investigation suggest that clinical use of oral neomycin implies relatively little risk of ototoxicity.
据报道，口服新霉素很少引起耳毒性。大多数关于口服新霉素导致听力损失的报告都是病例研究。一项针对儿科样本的前瞻性研究表明，17名儿童中有9名在2至8千赫兹的频率范围内听力显著下降。据我们所知，目前还没有关于成年样本的此类已发表的前瞻性研究，因此对于口服新霉素耳毒性的真实发生率或性质知之甚少。这项前瞻性研究展示了30名成年受试者长期使用口服新霉素的结果。在250 - 20000赫兹的频率范围内对听力敏感度进行了连续监测。30名受试者中有两名随后出现了耳毒性。因此，这项调查结果表明，口服新霉素的临床使用意味着耳毒性风险相对较小。
